Immunosignature: Serum Antibody Profiling for Cancer Diagnostics.

Biomarkers for preclinical diagnosis of cancer are valuable tools for detection of malignant tumors at early stages in groups at risk and screening healthy people, as well as monitoring disease recurrence after treatment of cancer. However the complexity of the body's response to the pathological processes makes it virtually impossible to evaluate this response to the development of the disease using a single biomarker that is present in the serum at low concentrations. An alternative approach to standard biomarker analysis is called immunosignature. Instead of going after biomarkers themselves this approach rely on the analysis of the humoral immune response to molecular changes associated with the development of pathological processes. It is known that antibodies are produced in response to proteins expressed during cancer development. Accordingly, the changes in antibody repertoire associated with tumor growth can serve as biomarkers of cancer. Immunosignature is a highly sensitive method for antibody repertoire analysis utilizing high density peptide microarrays. In the present review we discuss modern methods for antibody detection, as well as describe the principles and applications of immunosignature in research and clinical practice.

• Publication year

  2015

• Venue

  Asian Pacific Journal of Cancer Prevention

• Publication date

  2015-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.7314/APJCP.2015.16.12.4833PMID 26163599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015influential reference
• Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens

  2014cited by this paper
• Immunosignature system for diagnosis of cancer

  2014cited by this paper
• Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib

  2014cited by this paper
• Relationship between breast cancer and levels of serum thyroid hormones and antibodies: a meta-analysis.

  2014cited by this paper
• Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of esophageal cancer.

  2014cited by this paper
• Scalable high-density peptide arrays for comprehensive health monitoring

  2014cited by this paper
• The riddle of protein diagnostics: future bleak or bright?

  2013cited by this paper
• A new method combining sequential immunoaffinity depletion and differential in gel electrophoresis to identify autoantibodies as cancer biomarkers.

  2013cited by this paper
• Immunosignaturing: a critical review.

  2013cited by this paper
• Feasibility of an early Alzheimer's disease immunosignature diagnostic test.

  2013cited by this paper
• Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

  2013cited by this paper
• Tumor-associated autoantibodies as diagnostic and prognostic biomarkers

  2012cited by this paper
• Comparative study of classification algorithms for immunosignaturing data

  2012cited by this paper
• Immunosignaturing Can Detect Products from Molecular Markers in Brain Cancer

  2012cited by this paper
• Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer.

  2012cited by this paper
• Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas

  2012cited by this paper
• Autoreactive antibodies raised by self derived de novo peptides can identify unrelated antigens on protein microarrays. Are autoantibodies really autoantibodies?

  2012cited by this paper
• Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.

  2012cited by this paper
• Physical Characterization of the “Immunosignaturing Effect”

  2012cited by this paper
• TraML—A Standard Format for Exchange of Selected Reaction Monitoring Transition Lists

  2011cited by this paper
• Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations

  2011cited by this paper
• A multi-analyte serum test for the detection of non-small cell lung cancer

  2010cited by this paper
• A general method for characterization of humoral immunity induced by a vaccine or infection.

  2010cited by this paper
• Serum autoantibodies as biomarkers for early cancer detection

  2009cited by this paper
• Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays.

  2009cited by this paper
• Design of high-density antibody microarrays for disease proteomics: key technological issues.

  2009cited by this paper
• The cancer biomarker problem

  2008cited by this paper
• Strategies for discovering novel cancer biomarkers through utilization of emerging technologies

  2008cited by this paper
• Autoantibodies in breast cancer: their use as an aid to early diagnosis.

  2007cited by this paper
• Autoantibodies in lung cancer: possibilities for early detection and subsequent cure

  2007cited by this paper
• Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery*

  2007cited by this paper
• Cancer Immunomics

  2007cited by this paper
• Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer*

  2006cited by this paper
• Identification of biomarkers from mass spectrometry data using a "common" peak approach

  2006cited by this paper
• Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis.

  2005cited by this paper
• Autoantibody signatures in prostate cancer.

  2005cited by this paper
• B-Raf specific antibody responses in melanoma patients

  2004cited by this paper
• Identification of circulating antibodies to tumor‐associated proteins for combined use as markers of non‐small cell lung cancer

  2004cited by this paper
• Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.

  2003cited by this paper
• Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens.

  2003cited by this paper
• Targeting of tumor associated antigens in renal cell carcinoma using proteome‐based analysis and their clinical significance

  2002cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001influential reference
• Identification of tumor antigens in renal cell carcinoma by serological proteome analysis

  2001cited by this paper
• Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity.

  2001cited by this paper
• Printing proteins as microarrays for high-throughput function determination.

  2000cited by this paper
• Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.

  2000cited by this paper
• Antigens recognized by autologous antibody in patients with renal‐cell carcinoma

  1999cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper

• Measurement of the IgM and IgG Autoantibody Immune Responses in Human Serum has High Predictive Value for the Presence of Colorectal Cancer

  2019cites this paper
• High-throughput epitope profiling of antibodies in the plasma of Alzheimer’s disease patients using random peptide microarrays

  2019cites this paper
• Liquid biopsy for pediatric central nervous system tumors

  2018cites this paper
• Humoral Immunity Profiling of Subjects with Myalgic Encephalomyelitis Using a Random Peptide Microarray Differentiates Cases from Controls with High Specificity and Sensitivity

  2016cites this paper